Cyclacel Pharmaceuticals

$7.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (+0.95%) Today

+$0.07 (+0.94%) As of 1:34 PM UTC after-hours

Why Robinhood?

You can buy or sell CYCC and other stocks, options, and ETFs commission-free!

About CYCC

Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ. The listed name for CYCC is Cyclacel Pharmaceuticals, Inc. Common Stock.

CEO

Spiro Rombotis

Employees

Headquarters

Berkeley Heights, New Jersey

Founded

1996

Market Cap

38.94M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

364.63K

High Today

$7.52

Low Today

$7.23

Open Price

$7.38

Volume

144.99K

52 Week High

$19.25

52 Week Low

$3.12

Collections

CYCC Earnings

-$2.90

-$1.93

-$0.97

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 24, After Hours